

James X Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7408496/publications.pdf>

Version: 2024-02-01

40
papers

7,172
citations

331670

21
h-index

361022

35
g-index

40
all docs

40
docs citations

40
times ranked

11264
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. <i>Nature Biotechnology</i> , 2013, 31, 1023-1031. | 17.5 | 1,785 |
| 2 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961. | 13.7 | 1,261 |
| 3 | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 75-87. | 10.7 | 975 |
| 4 | Emergence of Constitutively Active Estrogen Receptor- β Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1757-1767. | 7.0 | 529 |
| 5 | Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998. | 9.4 | 310 |
| 6 | <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219. | 9.4 | 278 |
| 7 | ^{Non-V600} <i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2624-2630. | 1.6 | 267 |
| 8 | Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic <i>BRCA1</i> or <i>BRCA2</i> mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275. | 1.4 | 222 |
| 9 | Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617. | 1.4 | 192 |
| 10 | A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. <i>PLoS Computational Biology</i> , 2018, 14, e1005965. | 3.2 | 191 |
| 11 | <i>ALK</i> , <i>ROS1</i> , and <i>NTRK</i> Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, . | 6.3 | 183 |
| 12 | Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. <i>Oncologist</i> , 2017, 22, 1478-1490. | 3.7 | 176 |
| 13 | Genomic Profiling of Small-Bowel Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 1546. | 7.1 | 154 |
| 14 | A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 1053-1066. | 2.8 | 147 |
| 15 | Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9017-9017. | 1.6 | 129 |
| 16 | Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. <i>Oncotarget</i> , 2017, 8, 43653-43661. | 1.8 | 85 |
| 17 | Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. <i>Cancer Research</i> , 2017, 77, 509-519. | 0.9 | 75 |
| 18 | Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. <i>Oncologist</i> , 2016, 21, 1315-1325. | 3.7 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?. <i>Leukemia</i> , 2018, 32, 1561-1566. | 7.2 | 39 |
| 20 | First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, . | 5.0 | 26 |
| 21 | Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3587-3587. | 1.6 | 26 |
| 22 | Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1523-1523. | 1.6 | 10 |
| 23 | Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5512-5512. | 1.6 | 10 |
| 24 | Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i> -altered non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33995-34008. | 1.8 | 9 |
| 25 | Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP).. <i>Journal of Clinical Oncology</i> , 2016, 34, 528-528. | 1.6 | 6 |
| 26 | Mutational burden of tumors with primary site unknown.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3039-3039. | 1.6 | 6 |
| 27 | Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP).. <i>Journal of Clinical Oncology</i> , 2015, 33, 11084-11084. | 1.6 | 5 |
| 28 | Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5536-5536. | 1.6 | 2 |
| 29 | BRCA1/2 reversion mutations revealed in breast and gynecologic cancers sequenced during routine clinical care using tissue or liquid biopsy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5551-5551. | 1.6 | 2 |
| 30 | Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5545-5545. | 1.6 | 2 |
| 31 | Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5591-5591. | 1.6 | 2 |
| 32 | Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 532-532. | 1.6 | 1 |
| 33 | Loss of heterozygosity in multiple myeloma: A role for PARP inhibition?. <i>Journal of Clinical Oncology</i> , 2017, 35, 8026-8026. | 1.6 | 1 |
| 34 | Comprehensive genomic profiling (CGP) to assess mutational load in gastric and esophageal adenocarcinomas: Implications for immunotherapies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 66-66. | 1.6 | 1 |
| 35 | <i>BRCA1/2</i> reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5024-5024. | 1.6 | 1 |
| 36 | Frequent LOH of CYP2D6 in ER+ breast cancer determined by next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 534-534. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway.. Journal of Clinical Oncology, 2015, 33, 3522-3522. | 1.6 | 0 |
| 38 | Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway.. Journal of Clinical Oncology, 2015, 33, 530-530. | 1.6 | 0 |
| 39 | Intratumoral heterogeneity of cancer driver genomic alterations across several tumor types.. Journal of Clinical Oncology, 2015, 33, 1558-1558. | 1.6 | 0 |
| 40 | BRCA1/2 reversion mutations in pancreaticobiliary cancer identified from patient biopsies.. Journal of Clinical Oncology, 2017, 35, 4130-4130. | 1.6 | 0 |